BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22588067)

  • 21. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
    Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral lymphatics and lymphatic vessel invasion detected by D2-40 are essential for lymph node metastasis in bladder transitional cell carcinoma.
    Ma Y; Hou Y; Liu B; Li X; Yang S; Ma J
    Anat Rec (Hoboken); 2010 Nov; 293(11):1847-54. PubMed ID: 20730866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors.
    Veschi V; Petroni M; Bartolazzi A; Altavista P; Dominici C; Capalbo C; Boldrini R; Castellano A; McDowell HP; Pizer B; Frati L; Screpanti I; Gulino A; Giannini G
    Cell Death Dis; 2014 Mar; 5(3):e1100. PubMed ID: 24603328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors.
    Maitra A; Yashima K; Rathi A; Timmons CF; Rogers BB; Shay JW; Gazdar AF
    Cancer; 1999 Feb; 85(3):741-9. PubMed ID: 10091748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas.
    Ramani P; Sowa-Avugrah E; May MT
    Virchows Arch; 2015 Sep; 467(3):319-27. PubMed ID: 26199132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carbonic anhydrase IX up-regulation is associated with adverse clinicopathologic and biologic factors in neuroblastomas.
    Dungwa JV; Hunt LP; Ramani P
    Hum Pathol; 2012 Oct; 43(10):1651-60. PubMed ID: 22436629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral but not peritumoral lymphatic vessel density measured by D2-40 expression predicts poor outcome in gastric cancer--ROC curve analysis to find cut-off point.
    Donizy P; Rudno-Rudzinska J; Halon A; Dziegala M; Kabarowski J; Frejlich E; Dziegiel P; Kielan W; Matkowski R
    Anticancer Res; 2014 Jun; 34(6):3113-8. PubMed ID: 24922680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma.
    de Souza DR; Sanabani SS; de Souza AC; Filho Odone V; Epelman S; Bendit I
    Pediatr Blood Cancer; 2011 May; 56(5):749-56. PubMed ID: 21154590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
    Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
    Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of NTRK family gene expression in neuroblastomas.
    Light JE; Koyama H; Minturn JE; Ho R; Simpson AM; Iyer R; Mangino JL; Kolla V; London WB; Brodeur GM
    Pediatr Blood Cancer; 2012 Aug; 59(2):226-32. PubMed ID: 21990266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implication of unfavorable histology, MYCN amplification and diploidy for stage I and II neuroblastomas.
    de Buys Roessingh AS; Rougemont AL; Wiesenauer C; Barrette S; Bouron-Dal Soglio D; Lallier M
    Eur J Pediatr Surg; 2008 Dec; 18(6):410-4. PubMed ID: 19012235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathologic features of peripheral neuroblastic tumors].
    Yang BF; Fu LB; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):305-10. PubMed ID: 24004586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of MYCN amplification and 1p deletion in neuroblastomas with high tumor vascularity.
    Ozer E; Altungoz O; Unlu M; Aygun N; Tumer S; Olgun N
    Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):181-6. PubMed ID: 17525631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.
    van Wezel EM; Decarolis B; Stutterheim J; Zappeij-Kannegieter L; Berthold F; Schumacher-Kuckelkorn R; Simon T; Fiocco M; van Noesel MM; Caron HN; van der Schoot CE; Hero B; Tytgat GAM
    Eur J Cancer; 2016 Feb; 54():149-158. PubMed ID: 26796600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
    Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
    Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.